Bernt Johan von Scholten

Scopus Author ID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 11

Top Topics

Systematic Review

Chronic Kidney Disease

Top Venues

JMIR research protocols

Diabetes, obesity & metabolism

Expert review of clinical immunology

Clinical journal of the American Society of Nephrology : CJASN

This page only lists publications with an associated author ORCID identifier.

Publications

Esben Iversen, Katrine McLain Christensen, Anne Byriel Walls, Mie Klessen Eickhoff, Bernt Johan von Scholten, Marie Frimodt-Møller, Tine Willum Hansen, Stephen C Bain, Ellen Burgess, Viktor Rotbain Curovic, Morten Baltzer Houlind
Performance of new and panel CKD-EPI equations in European adults with type 2 diabetes. Diabetes, obesity & metabolism (2024)
Esben Iversen, Katrine McLain Christensen, Anne Byriel Walls, Mie Klessen Eickhoff, Bernt Johan von Scholten, Marie Frimodt-Møller, Tine Willum Hansen, Stephen C Bain, Ellen Burgess, Viktor Rotbain Curovic, Morten Baltzer Houlind
Performance of new and panel CKD-EPI equations in European adults with type 2 diabetes. Diabetes, obesity & metabolism 26 (6) (2024)
Tanja Fredensborg Holm, Flemming Witt Udsen, Marit Eika Jørgensen, Morten Hasselstrøm Jensen, Bernt Johan von Scholten, Ole Kristian Hejlesen, Stine Hangaard
The Effectiveness of Digital Health Lifestyle Interventions on People With Prediabetes: Protocol for a Systematic Review, Meta-Analysis, and Meta-Regression. JMIR research protocols 13 (2024)
Tanja Fredensborg Holm, Flemming Witt Udsen, Marit Eika Jørgensen, Morten Hasselstrøm Jensen, Bernt Johan von Scholten, Ole Kristian Hejlesen, Stine Hangaard
The Effectiveness of Digital Health Lifestyle Interventions on People With Prediabetes: Protocol for a Systematic Review, Meta-Analysis, and Meta-Regression. JMIR research protocols 13 (2024)
Tanja Fredensborg Holm, Flemming Witt Udsen, Marit Eika Jørgensen, Morten Hasselstrøm Jensen, Bernt Johan von Scholten, Ole Kristian Hejlesen, Stine Hangaard
The Effectiveness of Digital Health Lifestyle Interventions on People With Prediabetes: Protocol for a Systematic Review, Meta-Analysis, and Meta-Regression. JMIR research protocols 13 (2024)
Tanja Fredensborg Holm, Flemming Witt Udsen, Marit Eika Jørgensen, Morten Hasselstrøm Jensen, Bernt Johan von Scholten, Ole Kristian Hejlesen, Stine Hangaard
The Effectiveness of Digital Health Lifestyle Interventions on People With Prediabetes: Protocol for a Systematic Review, Meta-Analysis, and Meta-Regression. JMIR research protocols 13 (2024)
Esben Iversen, Katrine McLain Christensen, Anne Byriel Walls, Mie Klessen Eickhoff, Bernt Johan von Scholten, Marie Frimodt-Møller, Tine Willum Hansen, Stephen C Bain, Ellen Burgess, Viktor Rotbain Curovic, Morten Baltzer Houlind
Performance of new and panel CKD-EPI equations in European adults with type 2 diabetes. Diabetes, obesity & metabolism 26 (6) (2024)
Bernt Johan von Scholten, Frederik Flindt Kreiner, Søren Rasmussen, Peter Rossing, Thomas Idorn
The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice. Therapeutic advances in endocrinology and metabolism 13 (2022)
Frederik Flindt Kreiner, Jordan M Kraaijenhof, Matthias von Herrath, G Kees Kornelis Hovingh, Bernt Johan von Scholten
Interleukin 6 in diabetes, chronic kidney disease, and cardiovascular disease: mechanisms and therapeutic perspectives. Expert review of clinical immunology 18 (4) (2022)
Johannes F E Mann, Vivian A Fonseca, Neil R Poulter, Itamar Raz, Thomas Idorn, Søren Rasmussen, Bernt Johan von Scholten, Ofri Mosenzon, null null
Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease. Clinical journal of the American Society of Nephrology : CJASN 15 (4) (2020)
Bernt Johan von Scholten, Frederik Persson, Signe Rosenlund, Jesper Eugen-Olsen, Tomasz Pielak, Jens Faber, Tine W Hansen, Peter Rossing
Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial. Diabetes, obesity & metabolism 19 (6) (2017)